Literature DB >> 26745555

Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.

Marcin Krawczyk1, Ewa Stachowska, Piotr Milkiewicz, Frank Lammert, Malgorzata Milkiewicz.   

Abstract

BACKGROUND: The adiponutrin (PNPLA3) p.I148M and transmembrane 6 superfamily member 2 (TM6SF2) p.E167K variants represent risk factors for non-alcoholic fatty liver disease (NAFLD). In this study, we assessed the effects of caloric restriction on liver phenotypes in NAFLD patients in relation to the PNPLA3 and TM6SF2 genotypes.
METHODS: We genotyped both variants in 143 individuals with NAFLD (55 females, age 18-74 years) and 180 controls (85 females, age 33-66 years). Liver steatosis was assessed using the ultrasound-based Hamaguchi score. A 4-month dietetic intervention, consisting of restriction of daily caloric intake without changes in physical activity, was performed.
RESULTS: Both PNPLA3 (p = 0.002) and TM6SF2 (p = 0.041) variants were associated with NAFLD before intervention. Overall, 88 patients completed the intervention, which led to a significant decrease of steatosis, ALT activities, body mass index, hip and waist circumferences, and waist-hip ratio (all p < 0.0001). Hepatic steatosis and anthropometric traits improved significantly (p < 0.05) in carriers of either PNPLA3 or TM6SF2 risk genotype. The improvement of phenotypic traits, apart from WHR (p = 0.02), was not modified by the presence of PNPLA3 or TM6SF2 variants.
CONCLUSIONS: The PNPLA3 and TM6SF2 polymorphisms are associated with NAFLD assessed by the Hamaguchi score. Neither PNPLA3 nor TM6SF2 risk alleles impair the response to dietetic intervention in NAFLD.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26745555     DOI: 10.1159/000441185

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

1.  Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

2.  The roles of transmembrane 6 superfamily member 2 rs58542926 polymorphism in chronic liver disease: A meta-analysis of 24,147 subjects.

Authors:  Xinpei Chen; Pengcheng Zhou; Luo De; Bo Li; Song Su
Journal:  Mol Genet Genomic Med       Date:  2019-07-15       Impact factor: 2.183

Review 3.  Nutrition and Genetics in NAFLD: The Perfect Binomium.

Authors:  Marica Meroni; Miriam Longo; Alice Rustichelli; Paola Dongiovanni
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

Review 4.  Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease.

Authors:  José Ignacio Martínez-Montoro; Isabel Cornejo-Pareja; Ana María Gómez-Pérez; Francisco J Tinahones
Journal:  Nutrients       Date:  2021-11-15       Impact factor: 5.717

Review 5.  The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases.

Authors:  Nicholas W S Chew; Bryan Chong; Cheng Han Ng; Gwyneth Kong; Yip Han Chin; Wang Xiao; Mick Lee; Yock Young Dan; Mark D Muthiah; Roger Foo
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

6.  PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.

Authors:  Beata Kruk; Roman Liebe; Małgorzata Milkiewicz; Ewa Wunsch; Joanna Raszeja-Wyszomirska; Frank Lammert; Piotr Milkiewicz; Marcin Krawczyk
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

Review 7.  PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease.

Authors:  Jin-Zhi Wang; Hai-Xia Cao; Jian-Neng Chen; Qin Pan
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

8.  The Association between SOCS1-1656G>A Polymorphism, Insulin Resistance and Obesity in Nonalcoholic Fatty Liver Disease (NAFLD) Patients.

Authors:  Agnieszka Kempinska-Podhorodecka; Ewa Wunsch; Piotr Milkiewicz; Ewa Stachowska; Malgorzata Milkiewicz
Journal:  J Clin Med       Date:  2019-11-08       Impact factor: 4.241

9.  Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown.

Authors:  Felice Cinque; Annalisa Cespiati; Rosa Lombardi; Andrea Costantino; Gabriele Maffi; Francesca Alletto; Lucia Colavolpe; Paolo Francione; Giovanna Oberti; Erika Fatta; Cristina Bertelli; Giordano Sigon; Paola Dongiovanni; Maurizio Vecchi; Silvia Fargion; Anna Ludovica Fracanzani
Journal:  Nutrients       Date:  2022-01-27       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.